Registration

Sign Up:

Work Email *

* Required

First Name *

* Required

Last Name *

* Required

Company *

* Required

Job Title *

* Required

Country *

* Required

City *

* Required

Are you currently working on or planning to work on AOCs or other Bioconjugates? *

Yes No * Required

Would you like to outsource CRO/CDMO to help you address the challenges in the discovery and development of AOCs or other Bioconjugates? *

Yes No * Required

What kind of support do you need? *

(*) denotes required form field(s)

WorkCast's registration process uses cookies, by submitting this registration form you agree to our cookie policy.

From ADC to XDC: Exploring the New Wave of Bio-conjugate Drugs — Antibody-Oligonucleotide Conjugates

Date: May 28 2025, Time: 11:00 am EDT | 8:00 am PDT | 5:00 pm CET

As antibody-drug conjugates (ADCs) continue their rapid rise, the industry is entering an exciting new era with the emergence of bioconjugates that extend beyond traditional ADCs. While these novel modalities offer tremendous promise, they also bring a distinct set of challenges throughout the drug development journey.

When compared to ADCs, Antibody–Oligonucleotide Conjugates (AOCs) andother bioconjugate modalities face unique challenges in their early development stages. Preparation, analysis, and both in vitro and in vivo studies are particularly critical.

Join us for this insightful webinar as our expert speaker shares valuable perspectives and real-world case studies on AOCs. You will also discover how WuXi XDC’s integrated discovery services accelerate early development for bioconjugate.

Key Learning Objectives

The evolving landscape of bioconjugate development
Key updates on AOC research and development
Real world case studies on AOC discovery
Accelerating Bio-Conjugate Discovery through WuXi XDC’s Integrated Service Platform

Presenters:

Dr. Jiawei Lu

Head of Bio-Conjugation Discovery Services / Sr. Director
WuXi XDC
View Biography